CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olson, D. C.
Right arrow Articles by Levine, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, D. C.
Right arrow Articles by Levine, A. J.

Cell Growth & Differentiation, Vol 5, Issue 1 61-71, Copyright © 1994 by American Association of Cancer Research


ARTICLES

The properties of p53 proteins selected for the loss of suppression of transformation

DC Olson and AJ Levine
Department of Molecular Biology, Princeton University, New Jersey 08544-1014.

The wild-type p53 protein can act as a suppressor of transformation in that it will block or reduce the formation of adenovirus E1A plus ras mediated transformants of primary rat embryo fibroblasts (C. A. Finlay et al., Cell, 57: 1083-1093, 1989). In those experiments, all of the transformed cell lines that arose selected for mutations in the transfected p53 gene, and many of these cell lines now express mutant p53 proteins. These mutant p53 genes are unusual because they were selected only for their inability to act as a transformation suppressor of other oncogenes as opposed to mutant p53 genes that arise spontaneously in tumors or transformed cell lines. p53 mutants that arise in tumors may be selected for several properties, and these mutants do have a number of phenotypes in common; for example, (a) they no longer block the cell division of transformed cells in culture (growth suppressor); (b) they cooperate with ras to transform rat embryo cells; (c) they enhance the plating efficiency of rat embryo cells; (d) some mutants have an altered protein conformation; (e) most mutants have a much longer half-life and greater concentration in the cells; and (f) mutants have lost or have a reduced ability to act as a transcription factor. Experiments were carried out to test whether the selection for p53 mutants that fail to block oncogene mediated transformation would also have some or all of the other properties of p53 mutants that arise in spontaneous tumors. Two mutants selected for their lost ability to block transformation were cloned, sequenced, and tested for all of the phenotypes listed above. The properties that these mutants had in common were (a) cooperation with ras to transform cells, (b) enhanced plating efficiency of cells, (c) elevated steady-state expression levels, and (d) a lost or reduced ability to act as a transcription factor.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
Y. Wang, S. Thorne, J. Hannock, J. Francis, T. Au, T. Reid, N. Lemoine, D. Kirn, and G. Hallden
A Novel Assay to Assess Primary Human Cancer Infectibility by Replication-Selective Oncolytic Adenoviruses
Clin. Cancer Res., January 1, 2005; 11(1): 351 - 360.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. Grigorian, S. Andresen, E. Tulchinsky, M. Kriajevska, C. Carlberg, C. Kruse, M. Cohn, N. Ambartsumian, A. Christensen, G. Selivanova, et al.
Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein: FUNCTIONAL CONSEQUENCES OF THEIR INTERACTION
J. Biol. Chem., June 22, 2001; 276(25): 22699 - 22708.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
E. A. Komarova, M. V. Chernov, R. Franks, K. Wang, G. Armin, C. R. Zelnick, D. M. Chin, S. S. Bacus, G. R. Stark, and A. V. Gudkov
Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo
EMBO J., March 15, 1997; 16(6): 1391 - 1400.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. Grigorian, S. Andresen, E. Tulchinsky, M. Kriajevska, C. Carlberg, C. Kruse, M. Cohn, N. Ambartsumian, A. Christensen, G. Selivanova, et al.
Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 Protein: FUNCTIONAL CONSEQUENCES OF THEIR INTERACTION
J. Biol. Chem., June 22, 2001; 276(25): 22699 - 22708.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1994 by the American Association of Cancer Research.